Frontiers in Drug Development Seminar on

Accelerating Pharma R&D with Artificial Intelligence and other Tools

Explore the potential of AI in minimising inefficiencies and uncertainty in drug discovery, design and development.

September 5, 2019, Basel

 

 Outline

Artificial Intelligence (AI) comprises all techniques enabling computers to mimic the human brain. Two applications of AI, used in drug development and healthcare, are machine learning and deep learning. Machine learning applies statistical methods with the ability to learn from data with or without explicit programming. Deep learning processes data, creates patterns for decision-making, and is learning from unstructured data.

The implementation of AI in drug discovery shows success in identifying and validating drug targets and proposing potent drug candidates and predicting their properties and possible toxicity risks. These potential applications provide the opportunity to minimise inefficiencies and uncertainty in drug discovery, design and repurposing.

We invite you to join us for the seminar and get insights to the prospects of “Accelerating Pharma R&D with Artificial Intelligence and other Tools”.

We are looking forward to welcoming you and your colleagues.

 

 

Format

1 day seminar, recognised for continuing professional development.

Credits

5 seminars over a period of two years equal 1 ECTS credit.
Accredited as continuing education by the Swiss Society of Pharmaceutical Medicine (SGPM) and the Swiss Society of Pharmaceutical Professionals (SwAPP).

Fee

680 CHF
580 CHF for ECPM Alumni and SwAPP/SGPM members
210 CHF for employees of universities and other nonprofit institutions


Cancellation Policy

overview ECPM courses